Evidence map›Paper›PMID 38955814›Full record

ArticleCardiovascular and interventional radiology2024

Long-Term Outcomes of Balloon TACE for HCC: An European Multicentre Single-Arm Retrospective Study.

Pierleone Lucatelli, Bianca Rocco, Thierry De Beare, Gontran Verset, Fabio Fucilli, Elio Damato, Alexandro Paccapelo, Lorenzo Braccischi, Makoto Taninokuchi Tomassoni, Ana-Maria Bucalau and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pierleone LucatelliInterventional Radiology Unit, Department of Diagnostic Medicine and Radiology, University ''La Sapienza" of Rome, Rome, Italy.
Bianca RoccoInterventional Radiology Unit, Department of Diagnostic Medicine and Radiology, University ''La Sapienza" of Rome, Rome, Italy. biancarocco.br@gmail.com.ORCID http://orcid.org/0000-0002-5073-2846
Thierry De BeareDepartment d'Anesthésie, de Chirurgie, et de Radiologie Interventionnelle, Gustave Roussy, 112 rue Edourad Vaillant, 94805, Villejuif, France.
Gontran VersetDepartment of Gastroenterology, Hepatopancreatology and Digestive Oncology C.U.B. Hôpital Erasme, Univerité Libre de Bruxelles, Brussels, Belgium.
Fabio FucilliRadiology Unit, S. De Bellis National Institute of Gastroenterology Research Hospital, Castellana Grotte (BARI), Bari, Italy.
Elio DamatoInterventional Radiology Unit, Department of Diagnostic Medicine and Radiology, University ''La Sapienza" of Rome, Rome, Italy.
Alexandro PaccapeloResearch and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Lorenzo BraccischiDepartment of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Makoto Taninokuchi TomassoniDepartment of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Ana-Maria BucalauDepartment of Gastroenterology, Hepatopancreatology and Digestive Oncology C.U.B. Hôpital Erasme, Univerité Libre de Bruxelles, Brussels, Belgium.
Carlo CatalanoInterventional Radiology Unit, Department of Diagnostic Medicine and Radiology, University ''La Sapienza" of Rome, Rome, Italy.
Cristina MosconiDepartment of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report response rates (using mRECIST), overall survival (OS), progression-free survival and local tumour recurrence-free survival (LRFS) of balloon-occluded transarterial chemoembolisation (bTACE) for hepatocellular carcinoma (HCC). MATERIALS AND

methodsPatients from five European centres treated with conventional or drug-eluting microsphere bTACE for HCC were included, and patients already lost to follow-up before 12 months were excluded. Possible factors contributing to LRFS and OS were evaluated with Cox proportional hazards models.

resultsSeventy-three patients were enrolled. The mean number of nodules per patient was 2.07(± 1.68), and the average maximum diameter of the nodules was 37 ± 19.9 mm. The response of the target lesion at 6 months was complete response (CR) in 58.9%, partial response (PR) in 28.8%, stable disease (SD) in 6.8% and progressive disease (PD) in 5.5%. The median follow-up time was 31 months; at the last follow-up, target tumour response was CR in 49.3%, PR in 12.3%, SD in 5.5% and PD 32.9%. Overall response at the last follow-up was CR in 17.8%, PR in 9.6%, SD 2.7% and PD in 69.9% (for new lesions in 37% of patients). Median OS was not reached; mean overall survival was 50.0 months, while median LRFS was 31.0 months. At uni- and multivariable analysis, only tumour maximum diameter was related to LRFS (hazard ratio [HR] = 1.021; 95% CI 1.004-1.038, P = 0.015).

conclusionsbTACE demonstrated high efficacy for HCC, with a complete response in 58.9% of patients, a median local recurrence-free survival of 31.0 months and a mean overall survival of 50.0 months.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAgedAged, 80 and overBalloon OcclusionEuropeFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeChemoembolisationDisease-free survivalHepatocellular carcinoma

Identifiers

PMID38955814
PMCPMC11303462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.